Seqens confirms changed ownership

CDMO Seqens has confirmed that its planned change of ownership has been completed, with SK Capital, a private investment firm focused on the specialty materials, chemicals and pharmaceuticals sectors, becoming the majority shareholder.

In parallel, the company has merged with SK’s existing subisidiary Wavelength Pharmaceuticals, an API manufacturer. Two new long-term institutional investors, Bpifrance and Nov Santé are also taking stakes, alongside the management and existing minority shareholders Mérieux Equity Partners, Ardian and Eximium. Bpifrance is the French national investment bank.

In addition, Seqens is divesting its non-core sodium bicarbonate, soda ash and sodium silicate production facilities in France and Singapore. These will remain under the control of Eurazeo and other historical shareholders.

As a result of these transactions, Seqnes said that it “is now emerging stronger and more focused, positioned as one of the world's leading players in pharmaceutical solutions and specialty ingredients”. In all, it will have sales of €1.1 billion/year, 24 industrial sites, ten R&D centres and 3,200 employees, with a portfolio of over 200 APIs and 500 pharmaceutical intermediates.